Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated respiratory health pilot in rural Hanoi
ACTRN12619000554167Phase 4Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide and formoterol in Chronic Respiratory Disease (CRD) and nicotine dependence, sponsored by Woolcock Institute of Medical Research. Primary endpoints: Proportion of patients with chronic respiratory disease who have at least one exacerbation during follow-up and Proportion of verified smoking abstinence among smoking participants enrolled in the programme. Started Mar 2019; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
Chronic Respiratory Disease (CRD)nicotine dependence
Beyond the preview
Go deeper on ACTRN12619000554167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000554167.